Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes

被引：38

作者：

Foley, J. E. ^{[1
]}

Ligueros-Saylan, M. ^{[1
]}

He, Y. -L ^{[2
]}

Holst, J. J. ^{[3
]}

Deacon, C. F. ^{[3
]}

Dunning, B. E. ^{[4
]}

Leone-Jones, A. ^{[5
]}

Yu, T. ^{[5
]}

Kelley, D. E. ^{[5
]}

机构：

[1] Novartis Pharmaceut Corp, E Hanover, NJ USA

[2] Novartis Inst Biomed Res, Cambridge, MA USA

[3] Univ Copenhagen, Copenhagen, Denmark

[4] Pharmawrite LLC, Princeton, NJ USA

[5] Univ Pittsburgh, Pittsburgh, PA USA

来源：

HORMONE AND METABOLIC RESEARCH | 2008年 / 40卷 / 10期

关键词：

D O I：

10.1055/s-2008-1078754

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

收藏

页码：727 / 730

页数：4

相关论文

共 14 条

[1] Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].

Ahrén, B ;

Landin-Olsson, M ;

Jansson, PA ;

Svensson, M ;

Holmes, D ;

Schweizer, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084

[2]

AZUMA K, 2008, J CLIN ENDOCR METAB, V93, P375

[3] Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].

Bosi, Emanuele ;

Camisasca, Riccardo Paolo ;

Collober, Carole ;

Rochotte, Erika ;

Garber, Alan J. .

DIABETES CARE, 2007, 30 (04) :890-895

[4] Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].

Deacon, CF ;

Nauck, MA ;

Meier, J ;

Hücking, K ;

Holst, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581

[5] Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs [J].

Deacon, CF ;

Wamberg, S ;

Bie, P ;

Hughes, TE ;

Holst, JJ .

JOURNAL OF ENDOCRINOLOGY, 2002, 172 (02) :355-362

[6] The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion [J].

El-Ouaghlidi, Andrea ;

Rehring, Erika ;

Holst, Jens J. ;

Schweizer, Anja ;

Foley, James ;

Holmes, David ;

Nauck, Michael A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) :4165-4171

[7] Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes [J].

Fonseca, V. ;

Schweizer, A. ;

Albrecht, D. ;

Baron, M. A. ;

Chang, I. ;

Dejager, S. .

DIABETOLOGIA, 2007, 50 (06) :1148-1155

[8]

Garber AJ, 2007, DIABETES, V56, pA134

[9] Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study [J].

Garber, A. J. ;

Schweizer, A. ;

Baron, M. A. ;

Rochotte, E. ;

Dejager, S. .

DIABETES OBESITY & METABOLISM, 2007, 9 (02) :166-174

[10] Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes [J].

Mari, A ;

Sallas, WM ;

He, YL ;

Watson, C ;

Ligueros-Saylan, M ;

Dunning, BE ;

Deacon, CF ;

Holst, JJ ;

Foley, JE .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) :4888-4894